Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report report published on Sunday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their price target on Aethlon Medical from $23.00 to $10.00 and set a buy rating on the stock in a report on Monday, March 4th.

Aethlon Medical Trading Down 9.5 %

AEMD opened at $1.36 on Friday. The business’s 50 day moving average is $1.64 and its 200-day moving average is $1.75. The stock has a market cap of $3.56 million, a PE ratio of -0.27 and a beta of 1.88. Aethlon Medical has a twelve month low of $1.33 and a twelve month high of $5.00.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.14). As a group, analysts forecast that Aethlon Medical will post -4.98 EPS for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.